Equillium to Present at Two Upcoming Investor Conferences
August 31 2022 - 8:00AM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders with high unmet medical need,
today announced that it will participate in a fireside chat
presentation at the Wells Fargo Healthcare Conference and a
corporate presentation at the H.C. Wainwright Annual Global
Investment Conference.
Management will provide a high-level overview of the company,
clinical assets, clinical programs and upcoming catalysts and
milestones. Management will also be available for one-on-one
meetings during both conferences.
Conference:
Wells Fargo Healthcare Conference
Location:
Encore Boston Harbor, Presentation Room
3
Date:
Wednesday, September 7
Time:
1:20 pm Pacific Time | 4:20 pm Eastern
Time
Conference:
H.C. Wainwright Annual Global Investment
Conference
Location:
Lotte New York Palace Hotel, Kennedy I,
4th Floor
Date:
Monday, September 12
Time:
12:00 pm Pacific Time | 3:00 pm Eastern
Time
Webcast access for both presentations will be available on the
“Events & Presentations” section of the Company’s website at
https://www.equilliumbio.com/investors/events-and-presentations/default.aspx.
An archived replay of both conferences will be available for 90
days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel immunomodulatory assets targeting
immuno-inflammatory pathways. Itolizumab, a first-in-class
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells,
is currently in a Phase 3 study for patients with acute
graft-versus-host disease (aGVHD) and is in a Phase 1b study for
patients with lupus/lupus nephritis. EQ101, a first-in-class
tri-specific cytokine inhibitor that selectively targets IL-2,
IL-9, and IL-15, is Phase 2 ready and expected to begin enrolling
patients in an alopecia areata study in the second half of 2022.
EQ102, a bi-specific cytokine inhibitor that selectively targets
IL-15 and IL-21, is ready for clinical development and expected to
begin enrolling patients in a Phase 1 study anticipated to include
normal healthy volunteers and celiac disease patients, in the
second half of 2022.
For more information, visit www.equilliumbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220831005201/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Sep 2023 to Sep 2024